PharmaFocus Today – Page 39 – media

Genfleet Pharmaceutical passed the Hong Kong Stock Exchange hearing

The Hong Kong Stock Exchange’s official website indicates that Jinfang Pharmaceuticals (Shanghai) Co., Ltd. has passed its hearing and is poised to list on the Hong Kong Stock Exchange. The prospectus states that Jinfang Pharmaceuticals, founded in 2017, is a biopharmaceutical company focused on developing novel treatment options for oncology (covering various lines of treatment for various solid tumors) as well as autoimmune and inflammatory diseases. Currently, Jinfang Pharmaceuticals has established a product pipeline consisting of eight drug candidates, five of which are in clinical development. Comment: Jinfang Pharmaceuticals, which has passed its Hong Kong Stock Exchange hearing, focuses on oncology and immune diseases. Its pipeline includes eight drug candidates, five of which are in clinical trials. A successful IPO could accelerate R&D, but the company faces intense competition in the field. https://finance.eastmoney.com/a/202508273495486977.html
- Source: drugdu
- 83
- August 29, 2025
Xinhua Bio completed tens of millions of US dollars in Series A financing

On August 25th, Xinhua Bio announced the completion of a multi-million dollar Series A financing round. The Series A+ round was led by Xingze Capital, while the Series A round was led by Sany Innovation Investment, with participation from other existing shareholders, including Sequoia China. The funds will be primarily used to advance the company’s core pipeline into global clinical trials, accelerate research and development, and provide more effective treatment options for patients worldwide. Comment: Xinhua Biopharma received tens of millions of US dollars in Series A financing. The funds will help its core pipeline enter global clinical trials, accelerate research and development, and highlight its research and development potential and market value in fields such as tumor immunology. https://finance.eastmoney.com/a/202508273495486977.html
- Source: drugdu
- 77
- August 29, 2025
Inxmed plans to go public in Hong Kong

According to the Hong Kong Stock Exchange’s official website, InxBio has submitted an application for listing on the Hong Kong Stock Exchange, with CITIC Securities and CCB International acting as joint sponsors. Founded in 2017, InxBio is a late-stage clinical-stage biotech company dedicated to improving current oncology treatments, which have limited efficacy. Its mission is to address the core challenge of cancer treatment: drug resistance caused by tumor defenses. Comment: Inspiron Biopharma plans to list in Hong Kong, focusing on addressing drug resistance in tumors. Its core products have potential. However, the company’s products are not commercialized, and it continues to lose money. Its capital needs are substantial, and its listing and profitability are uncertain. https://finance.eastmoney.com/a/202508273495486977.html
- Source: drugdu
- 88
- August 29, 2025
ReiPhase 3 clinical study of oral GLP-1RA orforglipron in obesity and type 2 diabetes was successful

Eli Lilly recently announced positive topline results from the Phase 3 ATTAIN-2 clinical trial of its investigational GLP-1 receptor agonist orforglipron. The study targeted obese or overweight adults with type 2 diabetes. In the ATTAIN-2 study, all three dose groups of orforglipron met the primary endpoint and all key secondary endpoints, achieving significant weight loss, clinically meaningful reductions in glycated hemoglobin (A1C), and improvements in cardiovascular risk factors at 72 weeks. Comment: Eli Lilly ‘s successful Phase 3 ATTAIN-2 clinical trial of orforglipron offers hope for patients with obesity and type 2 diabetes. The drug demonstrated significant weight loss and A1C reduction, while also improving cardiovascular risk factors. Oral administration is more convenient than injectable GLP-1RAs. If approved for marketing, it has the potential to reshape the treatment landscape, transform patient lifestyles, and usher in new market trends. https://finance.eastmoney.com/a/202508273495486977.html
- Source: drugdu
- 88
- August 29, 2025
Bayer’s small molecule PRMT5 inhibitor has been approved for clinical trials in China

The official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (CFDA) announced that Bayer has received implicit approval for clinical trials for its Category 1 new drug, BAY 3713372 tablets, intended for the treatment of methylthioadenosine phosphorylase-deficient (MTAP-DEL) solid tumors. This is an oral small molecule PRMT5 inhibitor. In March of this year, Bayer and Puhe Pharmaceuticals announced a global licensing agreement, granting them exclusive global rights to develop, manufacture, and commercialize this product. Comment: Bayer’s small molecule PRMT5 inhibitor has received clinical approval in China, which is expected to bring new hope to patients with MTAP-DEL solid tumors.It selectively targets cancer cells, has high safety, and has received technical support through cooperation with Puhe Pharmaceutical. Subsequent clinical data is highly anticipated. https://finance.eastmoney.com/a/202508273495486977.html
- Source: drugdu
- 94
- August 29, 2025
Net profit attributable to shareholders nearly doubled in the first half of the year

On the evening of August 27th, Xingqi Eye Medicine released its semi annual report for 2025. During the reporting period, the company achieved a revenue of 1162742877.58 yuan, an increase of 30.38% compared to the same period last year; The net profit attributable to shareholders of the listed company was 334826054.80 yuan, a significant increase of 97.75% compared to the same period last year. As a national high-tech enterprise mainly engaged in the subdivision of ophthalmic drugs, the company continues to focus on the ophthalmic field, adhere to the path of professional development, and continuously enhance its industry status and market competitiveness. During the reporting period, the company’s management team, under the leadership of the board of directors, focused on the company’s development strategy and business goals, consolidated the foundation of early development achievements, deepened resource integration, improved internal management level, actively and orderly promoted and implemented various important work ...
- Source: drugdu
- 142
- August 28, 2025
The National Healthcare Security Administration has announced the preliminary review of the list of drugs for the 2025 medical insurance and commercial insurance innovative drug catalog adjustment

According to the National Healthcare Security Administration, from August 12 to August 18, 2025, the National Healthcare Security Administration publicly announced the list of drugs that have passed the preliminary form review for the adjustment of the 2025 National Basic Medical Insurance, Maternity Insurance, Work Injury Insurance Drug Catalog, and Commercial Insurance Innovative Drug Catalog. During the public announcement period, a total of 75 feedback comments were received. According to the collected opinions, the National Healthcare Security Administration has reviewed and revised the relevant drug review results in accordance with the procedures. A total of 6 drug form review results have changed, all of which are drugs that have applied for the basic medical insurance catalog. The specific situation is: 1. Change the status of injectable risperidone microspheres to not pass the formal review; 2. Change the form review of triptorelin hydrochloride for injection to not pass; 3. Levodopa ...
- Source: drugdu
- 285
- August 28, 2025
FDA Accepts New Drug Application for Gadoquatrane

Bayer Global announced that its New Drug Application (NDA) for Gadoquatrane was accepted for review by the U.S. FDA. Gadoquatrane’s NDA was filed for contrast-enhanced magnetic resonance imaging (MRI) of the central nervous system (CNS) and other regions of the body in adults, and pediatric patients. Dr. Konstanze Diefenbach, head of radiology research & development at Bayer’s Pharmaceuticals Division touched on the importance of Gadoquatrane’s approval, saying, “Chronic diseases like cancer, neurological disorders like multiple sclerosis and cardiovascular conditions are on the rise, leading to an increase in medical imaging. Patients, especially those who require multiple examinations over the course of their lives, can benefit from a reduced contrast media dosage.”1 What is Gadoquatrane? Gadoquatrane is an investigational extracellular macrocyclic contrast agent in clinical development for contrast enhancement in MRI. A low-dose gadolinium-based contrast agent featuring a distinct tetrameric structure with high stability and high relativity.1 The agent is part ...
- Source: drugdu
- 92
- August 28, 2025
FDA Urges Safe Use of Hyperbaric Oxygen Therapy Devices

By Stephanie Brown HealthDay ReporterWEDNESDAY, Aug. 27, 2025 (HealthDay News) — The U.S. Food and Drug Administration has sent letters to health care providers alerting them to the importance of following manufacturer instructions for the safe use of hyperbaric oxygen therapy (HBOT) devices. HBOT uses a pressurized chamber to deliver 100 percent oxygen, helping the lungs absorb more oxygen to support healing and fight infections, according to the FDA. The agency has recently received reports of fires with HBOT devices causing serious injuries and deaths. Though rare, these events highlight the importance of following manufacturer instructions to reduce risks, the FDA notes. The agency advises health care providers to follow strict fire prevention and safety measures with HBOT devices, including proper grounding. Staff working with HBOT devices should receive ongoing training and always keep in mind that high concentrations of oxygen increase the risk for fire. Patients need to be ...
- Source: drugdu
- 79
- August 28, 2025
Telpotide will surpass semaglutide in all aspects, and it will be around next year

If the GLP-1 drug battle between Novo Nordisk and Eli Lilly were a football match, then 2021-2025 would be the first half, with Novo Nordisk’s earlier launches giving Eli Lilly’s product a head start. However, the situation seems poised to reverse in the second half, which begins in 2026. In 2026, we will achieve comprehensive transcendence According to Bloomberg’s forecast, Mounjaro and Zepbound will surpass Ozempic and Wegovy in 2026, and the gap will widen significantly in the next three years (Figure 1). Figure 1 Historical sales and future sales forecast trends of Wegovy, Ozempic, Mounjaro, and Zepbound Image source: Bloomberg In 2025, Novo’s semaglutide combination (Ozempic + Wegovy) will have a total revenue of US$33.6 billion, still higher than Lilly’s tirzepatide combination (Mounjaro + Zepbound) of US$31.1 billion; by 2026, the positions will be reversed, with Eli Lilly’s tirzepatide products totaling US$40.8 billion, ahead of Novo Nordisk’s semaglutide of ...
- Source: drugdu
- 91
- August 28, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.